German and US firms pool orthopaedic technology:
This article was originally published in Clinica
Executive Summary
US company Orquest has linked with Biopharm, of Heidelberg, Germany, to pool proprietary technologies. The German company will contribute MP52, a novel recombinant growth factor bone morphologic protein, while Mountain View, California-based Orquest will put in "unique proprietary materials and know-how for developing and assembling combinations of growth factors and matrices". The first product is expected to be HealosMP52 for spinal fusion, which is being developed with Sulzer SpineTech and is about to enter clinical trials in the US and Europe.